Abstract
An enzyme and reduction-activatable gemcitabine prodrug (TPE-GEM-RGD) with aggregation-induced emission (AIE) properties was designed for targeted and image-guided cancer therapy. TPE-GEM-RGD was successfully used for intracellular light-up imaging and glutathione (GSH)-responsive release of gemcitabine to suppress pancreatic cancer cells.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
